1-11 of 11
Jonathan Cebon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers

Available to Purchase
Oliver Klein, Damien Kee, Ben Markman, Michael Michael, Craig Underhill, Matteo S. Carlino, Louise Jackett, Caroline Lum, Clare Scott, Adnan Nagrial, Andreas Behren, Jane Y. So, Jodie Palmer, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4454–4459.
https://doi.org/10.1158/1078-0432.CCR-20-0621
Published: 01 September 2020
View articletitled, Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Open the PDF for Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers in another window
Includes: Supplementary data
Journal Articles

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma

Available to Purchase
Miles C. Andrews, Natalie Turner, Janis Boyd, Andrew W. Roberts, Andrew P. Grigg, Andreas Behren, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (23): 5222–5234.
https://doi.org/10.1158/1078-0432.CCR-15-0393
Published: 30 November 2015
View articletitled, Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma
Open the PDF for Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma

Available to Purchase
Katherine Woods, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4021–4023.
https://doi.org/10.1158/1078-0432.CCR-13-1349
Published: 31 July 2013
View articletitled, Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma
Open the PDF for Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma in another window
Includes: Supplementary data
Journal Articles

Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4

Available to Purchase
Oliver Klein, Lisa M. Ebert, Theo Nicholaou, Judy Browning, Sarah E. Russell, Marina Zuber, Heather M. Jackson, Nektaria Dimopoulos, Bee Shin Tan, Axel Hoos, Immanuel F. Luescher, Ian D. Davis, Weisan Chen, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2507–2513.
https://doi.org/10.1158/1078-0432.CCR-08-2424
Published: 01 April 2009
View articletitled, Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
Open the PDF for Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4 in another window
Journal Articles

Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial

Available to Purchase
Ian D. Davis, Ben Brady, Richard F. Kefford, Michael Millward, Jonathan Cebon, Birte K. Skrumsager, Ulrik Mouritzen, Lasse Tengbjerg Hansen, Kresten Skak, Dorthe Lundsgaard, Klaus Stensgaard Frederiksen, Paul E.G. Kristjansen, Grant McArthur
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2123–2129.
https://doi.org/10.1158/1078-0432.CCR-08-2663
Published: 16 March 2009
View articletitled, Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
Open the PDF for Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial in another window
Includes: Supplementary data
Journal Articles

Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

Available to Purchase
Theo Nicholaou, Lisa M. Ebert, Ian D. Davis, Grant A. McArthur, Heather Jackson, Nektaria Dimopoulos, Bee Tan, Eugene Maraskovsky, Lena Miloradovic, Wendie Hopkins, Linda Pan, Ralph Venhaus, Eric W. Hoffman, Weisan Chen, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2166–2173.
https://doi.org/10.1158/1078-0432.CCR-08-2484
Published: 16 March 2009
View articletitled, Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
Open the PDF for Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma in another window
Journal Articles

An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma

Available to Purchase
Ian D. Davis, Birte K. Skrumsager, Jonathan Cebon, Theo Nicholaou, John W. Barlow, Niels Peter Hundahl Moller, Kresten Skak, Dorthe Lundsgaard, Klaus Stensgaard Frederiksen, Peter Thygesen, Grant A. McArthur
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3630–3636.
https://doi.org/10.1158/1078-0432.CCR-07-0410
Published: 15 June 2007
View articletitled, An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma
Open the PDF for An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma in another window
Journal Articles

Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage

Available to Purchase
Catherine Barrow, Judy Browning, Duncan MacGregor, Ian D. Davis, Sue Sturrock, Achim A. Jungbluth, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (3): 764–771.
https://doi.org/10.1158/1078-0432.CCR-05-1544
Published: 07 February 2006
View articletitled, Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage
Open the PDF for Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage in another window
Journal Articles

Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1

Available to Purchase
Hilary A. Vaughan, Suzanne Svobodova, Duncan MacGregor, Sue Sturrock, Achim A. Jungbluth, Judy Browning, Ian D. Davis, Philip Parente, Yao-Tseng Chen, Elisabeth Stockert, Fiona St. Clair, Lloyd J. Old, Jonathan Cebon
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (24): 8396–8404.
https://doi.org/10.1158/1078-0432.CCR-04-0809
Published: 28 December 2004
View articletitled, Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1
Open the PDF for Immunohistochemical and Molecular Analysis of Human Melanomas for Expression of the Human Cancer-Testis Antigens NY-ESO-1 and LAGE-1 in another window
Journal Articles

NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors

Available to Purchase
Eugene Maraskovsky, Sigrid Sjölander, Debbie P. Drane, Max Schnurr, Thuy T. T. Le, Luis Mateo, Thomas Luft, Kelly-Anne Masterman, Tsin-Yee Tai, Qiyuan Chen, Simon Green, Anders Sjölander, Martin J. Pearse, Francois A. Lemonnier, Weisan Chen, Jonathan Cebon, Andreas Suhrbier
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (8): 2879–2890.
https://doi.org/10.1158/1078-0432.CCR-03-0245
Published: 20 April 2004
View articletitled, NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors
Open the PDF for NY-ESO-1 Protein Formulated in ISCOMATRIX Adjuvant Is a Potent Anticancer Vaccine Inducing Both Humoral and CD8+ T-Cell-Mediated Immunity and Protection against NY-ESO-1+ Tumors in another window
Journal Articles

A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer

Available to Purchase
Dishan H. Gunawardana, Russell L. Basser, Ian D. Davis, Jonathan Cebon, Paul Mitchell, Craig Underhill, Trevor J. Kilpatrick, Katrina Reardon, Michael D. Green, Peter Bardy, Pene Amor, David Crump, Siobhan Ng, Roger L. Nation, C. Glenn Begley
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 2056–2065.
Published: 01 June 2003
View articletitled, A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer
Open the PDF for A Phase I Study of Recombinant Human Leukemia Inhibitory Factor in Patients with Advanced Cancer in another window